此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Liraglutide as add-on to Insulin in Type 1 Diabetes (T1DMLIRA)

2015年3月31日 更新者:Christan SS Frandsen, MD、Hvidovre University Hospital

Treatment With Liraglutide as add-on to Insulin in Type 1 Diabetic Patients. Effects on Glycemic Control and Counterregulation and Cognitive Performance During Hypoglycaemia

The purpose of this study is to:

Part 1:

To investigate how 12 weeks treatment with liraglutide affects glycemic control in poorly controlled patients and how the treatment affects gastric emptying rate during hypoglycemia.

Part 2:

To investigate how 12 weeks treatment of type 1 diabetic patients with liraglutide affects counterregulatory hormones and cognitive performance during hypoglycemia.

研究概览

研究类型

介入性

注册 (实际的)

40

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Copenhagen
      • Hvidovre、Copenhagen、丹麦、2650
        • Dept. of Endocrinology, Hvidovre University Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age: 18-70 years
  • BMI: 18-28
  • HbA1c ≥ 8 %
  • No residual β-cell function (glucagon test with c-peptide < 60 pM)
  • Caucasian
  • Diagnosed with type 1 diabetes at 5 to 40 years of age (both inclusive).
  • Remission phase must be completed
  • Female participants must use adequate contraception
  • Informed consent

Exclusion Criteria:

  • Overt diabetes complications; creatinin > 130 µM, proliferative retinopathy, macroalbuminuria.
  • Autonomic neuropathy (RR-variation </=10 beats/min) and/or Orthostatic hypotension (OH).
  • Anemia, Hb concentration; female <7.0 mmol/l, male<8.0 mmol/l
  • Pregnancy or lactation
  • Epilepsy
  • Use of antiepileptic medication
  • Use of beta blockers
  • Previously apoplexy cerebri.
  • Any use of benzodiazepine within the last month
  • Any use of neuroleptic drugs within the last six months
  • Self-perceived hearing loss
  • Alcohol or drug abuse
  • Allergy to the medication or placebo.
  • Treatment with any medication affecting glucose metabolism.
  • Any disorder which in the investigators opinion could interfere with the safety and results of the trial

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Placebo + Insulin + Study 2
Study 2: Cognitive performance test
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
实验性的:Liraglutide + Insulin + Study 2
Study 2: Cognitive performance test
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
实验性的:Liraglutide + Insulin + Study 1
Study 1: Gastric emptying test
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
安慰剂比较:Placebo + Insulin + Study 1
Study 1: Gastric emptying test
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Change from baseline in HbA1c (glycosylated haemoglobin)
大体时间:Week 0, week 12
Week 0, week 12
Changes from baseline in EEG and cognitive performances
大体时间:week 0, week 12
week 0, week 12
Change from baseline in gastric emptying rate
大体时间:week 0, week 12
week 0, week 12

次要结果测量

结果测量
大体时间
Change from baseline in glycemic control (CGM)
大体时间:week 0, week 12
week 0, week 12
Change from baseline in total daily insulin dose
大体时间:week 0, week 12
week 0, week 12
Changes from baseline in the counterregulatory hormone responses during hypoglycemia
大体时间:week 0, week 12
week 0, week 12
Change from baseline in body weight
大体时间:week 0, week 12
week 0, week 12
Change from baseline in auditory evoked potentials (AEP) during hypoglycemia
大体时间:week 0, week 12
week 0, week 12
Change from baseline in corrected QTc-interval (QTc) during hypoglycemia
大体时间:week 0, week 12
week 0, week 12
Change from baseline in hypoglycemic symptom score
大体时间:week 0, week 12
week 0, week 12

其他结果措施

结果测量
大体时间
Frequency of Hypoglycemic episodes
大体时间:Week 0, week 12
Week 0, week 12

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2013年3月1日

初级完成 (实际的)

2014年10月1日

研究完成 (实际的)

2014年10月1日

研究注册日期

首次提交

2014年3月18日

首先提交符合 QC 标准的

2014年3月18日

首次发布 (估计)

2014年3月20日

研究记录更新

最后更新发布 (估计)

2015年4月1日

上次提交的符合 QC 标准的更新

2015年3月31日

最后验证

2015年3月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅